Skip to main content
PMC home page
The American Journal of Pathology logoLink to The American Journal of Pathology
. 1995 May;146(5):1131–1139.

c-myc copy number gains in bladder cancer detected by fluorescence in situ hybridization.

G Sauter 1, P Carroll 1, H Moch 1, A Kallioniemi 1, R Kerschmann 1, P Narayan 1, M J Mihatsch 1, F M Waldman 1
PMCID: PMC1869279  PMID: 7747807

Abstract

Amplification and overexpression of c-myc have been suggested as prognostic markers in human cancer. To assess the role of c-myc gene copy number alterations in bladder cancer, 87 bladder tumors were examined for c-myc aberrations by fluorescence in situ hybridization. Dual labeling hybridization with a repetitive pericentromeric probe specific for chromosome 8 and a probe for the c-myc locus (at 8q24) was performed to analyze c-myc copy number in relation to chromosome 8 copy number on a cell by cell basis. A clear-cut c-myc amplification (up to 40 to 150 copies per cell) was found in 3 tumors. There was a low level c-myc copy number increase in 32 of the remaining 84 tumors. There was no association of low level c-myc copy number increase with c-myc protein overexpression. This suggests that a c-myc gene copy number gain as detected by fluorescence in situ hybridization does not necessarily reflect a disturbed c-myc gene function but may indicate a structural chromosome 8 abnormality including gain of distal 8q. The strong association of low level c-myc (8q) gains with tumor grade (P < 0.0001), stage (P < 0.0001), chromosome polysomy (P < 0.0001), p53 protein expression (P = 0.0019), p53 deletion (P = 0.0403), and tumor cell proliferation (Ki67 labeling index; P = 0.0021) is consistent with a role of chromosome 8 alterations in bladder cancer progression.

Full text

PDF
1134

Images in this article

1133Figure 1
on p.1133

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Berger M. S., Greenfield C., Gullick W. J., Haley J., Downward J., Neal D. E., Harris A. L., Waterfield M. D. Evaluation of epidermal growth factor receptors in bladder tumours. Br J Cancer. 1987 Nov;56(5):533–537. doi: 10.1038/bjc.1987.238. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Bodner S. M., Minna J. D., Jensen S. M., D'Amico D., Carbone D., Mitsudomi T., Fedorko J., Buchhagen D. L., Nau M. M., Gazdar A. F. Expression of mutant p53 proteins in lung cancer correlates with the class of p53 gene mutation. Oncogene. 1992 Apr;7(4):743–749. [PubMed] [Google Scholar]
  3. Borg A., Baldetorp B., Fernö M., Olsson H., Sigurdsson H. c-myc amplification is an independent prognostic factor in postmenopausal breast cancer. Int J Cancer. 1992 Jul 9;51(5):687–691. doi: 10.1002/ijc.2910510504. [DOI] [PubMed] [Google Scholar]
  4. Coombs L. M., Pigott D. A., Sweeney E., Proctor A. J., Eydmann M. E., Parkinson C., Knowles M. A. Amplification and over-expression of c-erbB-2 in transitional cell carcinoma of the urinary bladder. Br J Cancer. 1991 Apr;63(4):601–608. doi: 10.1038/bjc.1991.139. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. DePinho R. A., Schreiber-Agus N., Alt F. W. myc family oncogenes in the development of normal and neoplastic cells. Adv Cancer Res. 1991;57:1–46. doi: 10.1016/s0065-230x(08)60994-x. [DOI] [PubMed] [Google Scholar]
  6. Evan G. I., Lewis G. K., Ramsay G., Bishop J. M. Isolation of monoclonal antibodies specific for human c-myc proto-oncogene product. Mol Cell Biol. 1985 Dec;5(12):3610–3616. doi: 10.1128/mcb.5.12.3610. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Evan G. I., Wyllie A. H., Gilbert C. S., Littlewood T. D., Land H., Brooks M., Waters C. M., Penn L. Z., Hancock D. C. Induction of apoptosis in fibroblasts by c-myc protein. Cell. 1992 Apr 3;69(1):119–128. doi: 10.1016/0092-8674(92)90123-t. [DOI] [PubMed] [Google Scholar]
  8. Hann S. R., King M. W., Bentley D. L., Anderson C. W., Eisenman R. N. A non-AUG translational initiation in c-myc exon 1 generates an N-terminally distinct protein whose synthesis is disrupted in Burkitt's lymphomas. Cell. 1988 Jan 29;52(2):185–195. doi: 10.1016/0092-8674(88)90507-7. [DOI] [PubMed] [Google Scholar]
  9. Kallioniemi A., Kallioniemi O. P., Citro G., Sauter G., DeVries S., Kerschmann R., Caroll P., Waldman F. Identification of gains and losses of DNA sequences in primary bladder cancer by comparative genomic hybridization. Genes Chromosomes Cancer. 1995 Mar;12(3):213–219. doi: 10.1002/gcc.2870120309. [DOI] [PubMed] [Google Scholar]
  10. Kallioniemi O. P., Kallioniemi A., Kurisu W., Thor A., Chen L. C., Smith H. S., Waldman F. M., Pinkel D., Gray J. W. ERBB2 amplification in breast cancer analyzed by fluorescence in situ hybridization. Proc Natl Acad Sci U S A. 1992 Jun 15;89(12):5321–5325. doi: 10.1073/pnas.89.12.5321. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Knowles M. A., Shaw M. E., Proctor A. J. Deletion mapping of chromosome 8 in cancers of the urinary bladder using restriction fragment length polymorphisms and microsatellite polymorphisms. Oncogene. 1993 May;8(5):1357–1364. [PubMed] [Google Scholar]
  12. Kotake T., Saiki S., Kinouchi T., Shiku H., Nakayama E. Detection of the c-myc gene product in urinary bladder cancer. Jpn J Cancer Res. 1990 Dec;81(12):1198–1201. doi: 10.1111/j.1349-7006.1990.tb02677.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Lane D. P. Cancer. p53, guardian of the genome. Nature. 1992 Jul 2;358(6381):15–16. doi: 10.1038/358015a0. [DOI] [PubMed] [Google Scholar]
  14. Livingstone L. R., White A., Sprouse J., Livanos E., Jacks T., Tlsty T. D. Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p53. Cell. 1992 Sep 18;70(6):923–935. doi: 10.1016/0092-8674(92)90243-6. [DOI] [PubMed] [Google Scholar]
  15. Locker A. P., Dowle C. S., Ellis I. O., Elston C. W., Blamey R. W., Sikora K., Evan G., Robins R. A. c-myc oncogene product expression and prognosis in operable breast cancer. Br J Cancer. 1989 Nov;60(5):669–672. doi: 10.1038/bjc.1989.337. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Masters J. R., Vesey S. G., Munn C. F., Evan G. I., Watson J. V. c-myc oncoprotein levels in bladder cancer. Urol Res. 1988;16(5):341–344. doi: 10.1007/BF00256039. [DOI] [PubMed] [Google Scholar]
  17. Matsumura K., Kallioniemi A., Kallioniemi O., Chen L., Smith H. S., Pinkel D., Gray J., Waldman F. M. Deletion of chromosome 17p loci in breast cancer cells detected by fluorescence in situ hybridization. Cancer Res. 1992 Jun 15;52(12):3474–3477. [PubMed] [Google Scholar]
  18. Merritt W. D., Weissler M. C., Turk B. F., Gilmer T. M. Oncogene amplification in squamous cell carcinoma of the head and neck. Arch Otolaryngol Head Neck Surg. 1990 Dec;116(12):1394–1398. doi: 10.1001/archotol.1990.01870120040005. [DOI] [PubMed] [Google Scholar]
  19. Moch H., Sauter G., Mihatsch M. J., Gudat F., Epper R., Waldman F. M. p53 but not erbB-2 expression is associated with rapid tumor proliferation in urinary bladder cancer. Hum Pathol. 1994 Dec;25(12):1346–1351. doi: 10.1016/0046-8177(94)90096-5. [DOI] [PubMed] [Google Scholar]
  20. Moch H., Sauter G., Moore D., Mihatsch M. J., Gudat F., Waldman F. p53 and erbB-2 protein overexpression are associated with early invasion and metastasis in bladder cancer. Virchows Arch A Pathol Anat Histopathol. 1993;423(5):329–334. doi: 10.1007/BF01607144. [DOI] [PubMed] [Google Scholar]
  21. Sasano H., Comerford J., Wilkinson D. S., Schwartz A., Garrett C. T. Serous papillary adenocarcinoma of the endometrium. Analysis of proto-oncogene amplification, flow cytometry, estrogen and progesterone receptors, and immunohistochemistry. Cancer. 1990 Apr 1;65(7):1545–1551. doi: 10.1002/1097-0142(19900401)65:7<1545::aid-cncr2820650716>3.0.co;2-8. [DOI] [PubMed] [Google Scholar]
  22. Sauter G., Deng G., Moch H., Kerschmann R., Matsumura K., De Vries S., George T., Fuentes J., Carroll P., Mihatsch M. J. Physical deletion of the p53 gene in bladder cancer. Detection by fluorescence in situ hybridization. Am J Pathol. 1994 Apr;144(4):756–766. [PMC free article] [PubMed] [Google Scholar]
  23. Sauter G., Haley J., Chew K., Kerschmann R., Moore D., Carroll P., Moch H., Gudat F., Mihatsch M. J., Waldman F. Epidermal-growth-factor-receptor expression is associated with rapid tumor proliferation in bladder cancer. Int J Cancer. 1994 May 15;57(4):508–514. doi: 10.1002/ijc.2910570412. [DOI] [PubMed] [Google Scholar]
  24. Sauter G., Moch H., Moore D., Carroll P., Kerschmann R., Chew K., Mihatsch M. J., Gudat F., Waldman F. Heterogeneity of erbB-2 gene amplification in bladder cancer. Cancer Res. 1993 May 15;53(10 Suppl):2199–2203. [PubMed] [Google Scholar]
  25. Sikora K., Evan G., Stewart J., Watson J. V. Detection of the c-myc oncogene product in testicular cancer. Br J Cancer. 1985 Aug;52(2):171–176. doi: 10.1038/bjc.1985.174. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Stewart J., Evan G., Watson J., Sikora K. Detection of the c-myc oncogene product in colonic polyps and carcinomas. Br J Cancer. 1986 Jan;53(1):1–6. doi: 10.1038/bjc.1986.1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Watson J. V., Stewart J., Cox H., Sikora K., Evan G. I. Flow cytometric quantitation of the c-myc oncoprotein in archival neoplastic biopsies of the colon. Mol Cell Probes. 1987 Jun;1(2):151–157. doi: 10.1016/0890-8508(87)90023-5. [DOI] [PubMed] [Google Scholar]
  28. Yao M., Shuin T., Misaki H., Kubota Y. Enhanced expression of c-myc and epidermal growth factor receptor (C-erbB-1) genes in primary human renal cancer. Cancer Res. 1988 Dec 1;48(23):6753–6757. [PubMed] [Google Scholar]

Articles from The American Journal of Pathology are provided here courtesy of American Society for Investigative Pathology

RESOURCES